OUR Pipeline
Ongoing projects
We have a diverse pipeline of multi-targeted therapies to make a difference in the lives of patients
Project Code
QD-101
PROJECT CODE
QD-101:
Indication: Advanced PXE with arterial calcifications. (ODD applied) IP: Market exclusivity Partners: Ectocalix (NET)QD-201
PROJECT CODE
QD-201:
Indication: Innovative administration for cancer IP: Device exclusivity Partners: Business partner pendingQD-301
PROJECT CODE
QD-301:
Indication: Adyuvant intraocular therapy for retinoblastoma (ODD pending) IP: Patent & market exclusivity Partners: Business partner pendingQD-401
PROJECT CODE
QD-401:
Indication: Osteoporosis IP: Exclusive formulation Partners: Partnership in progressIndication
Advanced PXE with arterial calcifications (ODD)
Innovative administration for cancer
Adyuvant intraocular
therapy for retinoblastoma (ODD pending)
therapy for retinoblastoma (ODD pending)
Osteoporosis
Preclinical
PK on going
Safety going
Phase I
2024
Phase II
2024-2026
Pending
2025
Phase III
2024-2025
Pending
Pending
2026
Market
EU
EU & NA
WW
EU & NA
ODD: Orphan Drug Designation -
PK: Pharmacokinetics -
WW: Worldwide -
EU: Europe -
NA: North America
Qualix assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information on this page as current or accurate after its publication date and should not make any decisions based on this information as it is subject to changes and/or updates at any time for any number of reasons (including but not limited to changes in company policies, outcomes of clinical trials, market changes, etc.).